

From: OC GCP Questions
To: [REDACTED]
Subject: RE: 1572 Form Question re Box 1 address
Date: Thursday, October 05, 2017 1:10:03 PM
Attachments: [REDACTED]

Good afternoon,

FDA's regulations and guidance are silent on the specific question you have raised. The guidance does recognize that there may be differences in an investigator's physical location and where the address where they receive mail.

I hope this information is helpful. Please contact us again at gcp.questions@fda.hhs.gov should you have additional questions.

Patrick J. McNeilly, Ph.D.
Senior Health Policy Analyst

**Office of Good Clinical Practice
U.S. Food and Drug Administration**



This communication does not constitute a written advisory opinion under 21 CFR 10.85, but rather is an informal communication under 21 CFR 10.85(k) which represents the best judgment of the employee providing it. This information does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed.

From: [REDACTED]
Sent: Wednesday, October 04, 2017 7:48 PM
To: OC GCP Questions
Subject: 1572 Form Question re Box 1 address

Dear Sir or Madam,

Is it acceptable for an investigator to provide only a PO Box as their address in box 1

(with no additional street address) if the PO Box is where they receive their mail?
Guidance states “The address is where the investigator can be reached by mail or in person. Usually this corresponds to the investigator’s work or business address.”

Thanks so much for your guidance.

Sincerely,

[REDACTED]

[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]

[REDACTED]

[REDACTED]